Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin

Abstract

The present application provides methods of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual, comprising systemically (e.g., intravenously or subcutaneously) administeringto the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, optionally further comprising administering a second agent (such as an anti-VEGF antibody, a proteasome inhibitor, or an alkylating agent).

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to U.S. Provisional Patent Application Serial No. 62 / 645,634, filed March 20, 2018, and U.S. Provisional Patent Application Serial No. 62 / 815,346, filed March 7, 2019. The entire contents of these applications are hereby incorporated by reference for all purposes. technical field [0003] The present application relates to methods and compositions for the treatment of CNS disorders by administering mTOR inhibitors (such as limus drugs, e.g. sirolimus or derivatives thereof) and Composition of albumin nanoparticles. Background technique [0004] Central nervous system diseases, also known as central nervous system disorders, are a group of neurological disorders that affect the structure or function of the brain or spinal cord, which together form the central nervous system (CNS). Current treatments include surgery and prescription drugs. However, many CNS disorders are...

AI Technical Summary

Problems solved by technology

However, many CNS disorders are difficult to treat due to natural barriers in the brain

Images